- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04957862
Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage
Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage for Accelerating Functional Rehabilitation (RESCUE-CHAIN): a Multi-center Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lijun Hou, MD,PhD
- Phone Number: +862181885671
- Email: houlijun@smmu.com
Study Contact Backup
- Name: Rongbin Chen, MD,PhD
- Phone Number: +862181885686
- Email: crb2588@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
The inclusion criteria are HICH patients who: (1) are ≥ 18 and ≤ 75 years old of either gender; (2) have evidence of supratentorial, deep-seated on CT scan with a volume of between 15 mL and 30 mL; (3) are within 24 h of ictus (<24 h between symptom onset and initial imaging); (4) have stable hematoma (hematoma growth<5 mL) for at least 12 h after diagnostic CT; (5) have no brain herniation and no needs for emergency surgery (clinical decisions made by 2 attending neurosurgeons); (6) have had no previous surgery on HICH or traumatic brain injury; (7) have GCS>8, NIH Stroke Scale (NIHSS)>5, Modified Rankin Scale (mRS) 3-5, and FMA scale<85; (8) fully understand the nature of the study and have signed informed consent.
The exclusion criteria are: (1) HICH caused by aneurysms, cerebrovascular malformations, tumors or trauma; (2) any pre-existing physical or mental disorder that could interfere with the functional assessment; (3) severe abnormal coagulation function, hematologic diseases or multiple hemorrhagic lesions; (4) excessive hematoma extending into the ventricular system with ventricular dilation; (5) concomitant diseases such as liver, kidney and heart failure; (6) rebleeding>5 mL or with surgical indications before allocation; (7) poor adherence or other unsuitable situations for the trial as determined by the investigators; (8) pregnant female.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: robotic assisted evacuation
In the intervention arm, patients will receive stereotactic robotic assisted HICH evacuation according to the protocol under general anesthesia.
|
On the day of surgery, the patient is placed in the prone position.
After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration.
Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point.
The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed.
After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm.
The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.
|
NO_INTERVENTION: Concomitant care
All enrolled HICH patients in this study will receive standard medical treatment in the first 3-4 weeks according to the ASA/AHA guideline .
Continued medical treatment is applied to patients in the control arm.
Both arms will receive identical rehabilitation therapy three times per week for 180 days at one facility.
Rehabilitation therapy includes identical physical therapy, occupational therapy, speech therapy, functional training, acupuncture and massage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
modified Rankin Scale (mRS) 0-2
Time Frame: 180 days after surgery
|
The modified Rankin Scale (mRS) is a single item, global outcomes rating scale for patients post-stroke.
It is used to categorize level of functional independence with reference to pre-stroke activities rather than on observed performance of a specific task.
|
180 days after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evacuation rate of HICH
Time Frame: at the first day after procedure, 30 days and 180 days during the follow-up period.
|
the ratio of effective volume reduction to the initial volume
|
at the first day after procedure, 30 days and 180 days during the follow-up period.
|
modified Rankin Scale (mRS) 0-1
Time Frame: 180 days after surgery
|
The modified Rankin Scale (mRS) is a single item, global outcomes rating scale for patients post-stroke.
It is used to categorize level of functional independence with reference to pre-stroke activities rather than on observed performance of a specific task.
|
180 days after surgery
|
between-group shift analysis in the mRS distribution
Time Frame: 180 days after surgery
|
The modified Rankin Scale (mRS) is a single item, global outcomes rating scale for patients post-stroke.
It is used to categorize level of functional independence with reference to pre-stroke activities rather than on observed performance of a specific task.
|
180 days after surgery
|
Extended Glasgow Outcome Scale (eGOS)
Time Frame: at 90- and 180-days after surgery.
|
The GOS-E adds to the original 5 GOS categories, with 3 additional categories.
The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.
|
at 90- and 180-days after surgery.
|
NIH Stroke Scale(NIHSS)
Time Frame: at 90- and 180-days after surgery.
|
The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss.
A trained observer rates the ability to answer questions and perform activities.
Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items.
The single patient assessment requires less than 10 minutes to complete.
The evaluation of stroke severity depends upon the ability of the observer to accurately and consistently assess the patient
|
at 90- and 180-days after surgery.
|
Barthel Index for Activities of Daily Living (ADL-BI)
Time Frame: at 90- and 180-days after surgery.
|
The Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing.
The index also indicates the need for assistance in care.
|
at 90- and 180-days after surgery.
|
Fugl-Meyer Assessment (FMA)
Time Frame: at 90- and 180-days after surgery.
|
The FMA motor assessments for the upper (maximum score 66 points) and lower extremity (maximum score 34 points) are recommended as core measures to be used in every stroke recovery and rehabilitation trial.
|
at 90- and 180-days after surgery.
|
Motor Assessment Scale (MAS)
Time Frame: at 90- and 180-days after surgery.
|
The MAS is comprised of 8 items corresponding to 8 areas of motor function. Patients perform each task 3 times and the best performance is recorded. Supine to side lying Supine to sitting over the edge of a bed Balanced sitting Sitting to standing Walking Upper-arm function Hand movements Advanced hand activities |
at 90- and 180-days after surgery.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Tao Xu, MD,PhD, Shanghai Changzheng Hospital
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RESCUE-CHAIN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertensive Intracerebral Hemorrhage
-
Tongji HospitalUnknown
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
Huazhong University of Science and TechnologyUnknownHypertensive Intracerebral HemorrhageChina
-
First Affiliated Hospital, Sun Yat-Sen UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingIntracerebral Hemorrhage
-
Shanghai Changzheng HospitalThe First Affiliated Hospital of Nanchang University; Peking Union Medical... and other collaboratorsNot yet recruitingHypertensive Intracerebral HemorrhageChina
-
Wake Forest University Health SciencesActive, not recruitingStroke Hemorrhagic | Intracerebral Hemorrhage | Cerebral Edema | Intracerebral Hemorrhage, Hypertensive | Intracerebral Hemorrhage IntraparenchymalUnited States
-
University of RijekaCompletedBrain Injuries | Intraventricular Hemorrhage | Hypertensive Intracerebral Hemorrhage
-
Guangzhou University of Traditional Chinese MedicineLiaocheng People's Hospital; Lianjiang people's Hospital; Shenyang Second Hospital... and other collaboratorsUnknownTraditional Chinese Medicine | Intracerebral Hemorrhage, HypertensiveChina
-
The First People's Hospital of JingzhouCompletedHematoma Absorption and Neurological Function Recovery
-
University Hospital, GrenobleUnknownIntracranial Hemorrhage, HypertensiveFrance
Clinical Trials on Robotic Assisted Evacuation
-
Auris Health, Inc.CompletedLung Cancer | Pulmonary NoduleUnited States, Canada, China
-
St. Joseph's Healthcare HamiltonUnknown
-
Intuitive SurgicalActive, not recruitingThymoma | Myasthenia Gravis | Primary Lung Cancer | Benign Lung DiseaseUnited States
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Herning HospitalHerlev HospitalUnknownPain, Postoperative | Rehabilitation | Wound InfectionDenmark
-
Universita di VeronaRecruiting
-
Noah MedicalRecruitingLung Cancer | Nodes, LungHong Kong
-
Intuitive SurgicalActive, not recruitingColorectal Cancer | Benign or Malignant Rectal or Colon TumorsUnited States, Korea, Republic of
-
Corindus Inc.Japan Medicalnext, CoCompleted
-
Fondazione Don Carlo Gnocchi OnlusCompleted